Literature DB >> 10456973

Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Q Wang1, Y Wang, D M Hyde, P J Gotwals, V E Koteliansky, S T Ryan, S N Giri.   

Abstract

BACKGROUND: Transforming growth factor beta (TGF-beta) is a key mediator of collagen synthesis in the development of lung fibrosis. It has previously been shown that the administration of TGF-beta antibody and TGF-beta binding proteoglycan, decorin, reduced bleomycin (BL) induced lung fibrosis in animals. The present study was carried out to investigate whether intratracheal instillation of TGF-beta soluble receptor (TR) would minimise the BL induced lung fibrosis in hamsters.
METHODS: The effect of a recombinant TR (TGFbetaRII) on the lung collagen accumulation was evaluated in a BL hamster model of pulmonary fibrosis. Animals were divided into four groups and intratracheally injected with saline or BL at 6.5 U/4 ml/kg followed by intratracheal instillation of phosphate buffered saline (PBS) or 4 nmol TR in 0.3 ml twice a week. Twenty days after the first intratracheal instillation the hamsters were killed for bronchoalveolar lavage (BAL) fluid, biochemical, and histopathological analyses.
RESULTS: Treatment of hamsters with TR after intratracheal instillation of BL significantly reduced BL induced lung fibrosis as shown by decreases in the lung hydroxyproline level and prolyl hydroxylase activity, although they were still significantly higher than those of the saline control. Histopathological examination showed a considerable decrease in BL induced fibrotic lesions by TR treatment. However, TR did not prevent the BL induced increases in total cells and protein in the BAL fluid.
CONCLUSIONS: These results suggest that TR has antifibrotic potential in vivo and may be useful in the treatment of fibrotic diseases where increased TGF-beta is associated with excess collagen accumulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456973      PMCID: PMC1745567          DOI: 10.1136/thx.54.9.805

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  55 in total

1.  The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid.

Authors:  J F WOESSNER
Journal:  Arch Biochem Biophys       Date:  1961-05       Impact factor: 4.013

2.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung.

Authors:  P J Sime; Z Xing; F L Graham; K G Csaky; J Gauldie
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  The unglycosylated extracellular domain of type-II receptor for transforming growth factor-beta. A novel assay for characterizing ligand affinity and specificity.

Authors:  J F Goetschy; O Letourneur; N Cerletti; M A Horisberger
Journal:  Eur J Biochem       Date:  1996-10-15

4.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.

Authors:  V A Fadok; D L Bratton; A Konowal; P W Freed; J Y Westcott; P M Henson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis.

Authors:  R K Coker; G J Laurent; S Shahzeidi; P A Lympany; R M du Bois; P K Jeffery; R J McAnulty
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis.

Authors:  S N Giri; D M Hyde; R K Braun; W Gaarde; J R Harper; M D Pierschbacher
Journal:  Biochem Pharmacol       Date:  1997-12-01       Impact factor: 5.858

7.  Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis.

Authors:  G Gurujeyalakshmi; M A Hollinger; S N Giri
Journal:  Am J Respir Cell Mol Biol       Date:  1998-03       Impact factor: 6.914

8.  Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.

Authors:  J B Kopp; V M Factor; M Mozes; P Nagy; N Sanderson; E P Böttinger; P E Klotman; S S Thorgeirsson
Journal:  Lab Invest       Date:  1996-06       Impact factor: 5.662

9.  Expression of transforming growth factor-beta isoforms in human glomerular diseases.

Authors:  T Yamamoto; N A Noble; A H Cohen; C C Nast; A Hishida; L I Gold; W A Border
Journal:  Kidney Int       Date:  1996-02       Impact factor: 10.612

10.  Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII).

Authors:  M L Tsang; L Zhou; B L Zheng; J Wenker; G Fransen; J Humphrey; J M Smith; M O'Connor-McCourt; R Lucas; J A Weatherbee
Journal:  Cytokine       Date:  1995-07       Impact factor: 3.861

View more
  48 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  TGF-beta is a critical mediator of acute lung injury.

Authors:  J F Pittet; M J Griffiths; T Geiser; N Kaminski; S L Dalton; X Huang; L A Brown; P J Gotwals; V E Koteliansky; M A Matthay; D Sheppard
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli.

Authors:  Yong Zhou; James S Hagood; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 4.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Receptor-activated Smad localisation in bleomycin-induced pulmonary fibrosis.

Authors:  Hiroyuki Higashiyama; Daisuke Yoshimoto; Yuji Okamoto; Hideo Kikkawa; Satoshi Asano; Mine Kinoshita
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

6.  IL-10: Another therapeutic target in idiopathic pulmonary fibrosis?

Authors:  A B Millar
Journal:  Thorax       Date:  2006-10       Impact factor: 9.139

7.  Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis.

Authors:  Felix Chua; Sarah E Dunsmore; Peter H Clingen; Steven E Mutsaers; Steven D Shapiro; Anthony W Segal; Jürgen Roes; Geoffrey J Laurent
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

8.  Gene expression changes during the development of acute lung injury: role of transforming growth factor beta.

Authors:  Scott C Wesselkamper; Lisa M Case; Lisa N Henning; Michael T Borchers; Jay W Tichelaar; John M Mason; Nadine Dragin; Mario Medvedovic; Maureen A Sartor; Craig R Tomlinson; George D Leikauf
Journal:  Am J Respir Crit Care Med       Date:  2005-08-11       Impact factor: 21.405

9.  Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.

Authors:  Toru Oga; Toshiyuki Matsuoka; Chengcan Yao; Kimiko Nonomura; Shiho Kitaoka; Daiji Sakata; Yoshihiro Kita; Kiminobu Tanizawa; Yoshio Taguchi; Kazuo Chin; Michiaki Mishima; Takao Shimizu; Shuh Narumiya
Journal:  Nat Med       Date:  2009-11-29       Impact factor: 53.440

10.  Proapoptotic Bid is required for pulmonary fibrosis.

Authors:  G R Scott Budinger; Gökhan M Mutlu; James Eisenbart; Alyson C Fuller; Amy A Bellmeyer; Christina M Baker; Mindy Wilson; Karen Ridge; Terrence A Barrett; Vivian Y Lee; Navdeep S Chandel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.